Hospira fourth-qtr 2014 earnings beat expectations
US drugmaker Hospira (NYSE: HSP), a leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the fourth quarter and full-year 2014.
For the fourth quarter of 2014, net sales were $1.13 billion, up 3.9% ( and in line with analysts’ expectations), said Hospira, the subject of a $17 billion takeover bid from Pfizer (NYSE: PFE). On a US generally accepted accounting principles (GAAP) basis, fourth-quarter 2014 diluted earnings per share were $0.21 (+5.0%).
Excluding restructuring charges and other items, earnings were $0.53 a share, up 3.9%, well beating the expectations of analysts polled by Thomson Reuters of earnings per share of $0.42.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze